Vaccinia virus, a promising new therapeutic agent for pancreatic cancer
Chadwan Al Yaghchi1, Zhongxian Zhang2, Ghassan Alusi1
1Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
Abstract:
The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effects by multiple action mechanisms. Vaccinia virus has several inherent features that make it particularly suitable for use as an oncolytic agent. In this review, we will discuss the potential of vaccinia virus in the management of pancreatic cancer in light of our increased understanding of cellular and immunological mechanisms involved in the disease process as well as our extending knowledge in the biology of vaccinia virus.
Insights
Oncolytic viruses, like vaccinia virus, show promise for treating pancreatic cancer. This review explores vaccinia virus
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Pancreatic cancer has a poor prognosis, necessitating novel therapeutic approaches.
- Tumor-targeted oncolytic viruses offer a promising strategy by selectively destroying cancer cells and stimulating anti-tumor immune responses.
Purpose of the Study:
- To review the potential of vaccinia virus as an oncolytic agent for pancreatic cancer treatment.
- To discuss vaccinia virus' suitability based on its biological characteristics and interaction with tumor and immune mechanisms.
Main Methods:
- Literature review of existing research on oncolytic virotherapy, vaccinia virus biology, and pancreatic cancer.
- Analysis of the cellular and immunological mechanisms relevant to pancreatic cancer and vaccinia virus activity.
Main Results:
- Vaccinia virus possesses inherent features making it a suitable candidate for oncolytic virotherapy.
- Understanding of pancreatic cancer's complex biology and vaccinia virus' mechanisms is advancing.
Conclusions:
- Vaccinia virus holds significant potential for the management of pancreatic cancer.
- Further research into vaccinia virus-based therapies could lead to improved treatment strategies for pancreatic cancer patients.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies